Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation
Open Access
- 23 December 2025
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 14 (1) , 35
Abstract
Background: Semaglutide is a Glucagon-like peptide-1 receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM) and weight management. While its clinical benefits are well established, concerns have emerged over off-label use, underreporting of adverse drug reactions (ADRs), and prescribing disparities. Aims: To examine real-world prescribing pattern treatment efficacy and ADRs associated with semaglutide in a socioeconomically deprived United Kingdom (UK) locality, and to compare these with national data. Methods: A retrospective service evaluation was conducted using anonymised data from 1403 patients across 42 GP practices under a data share agreement across a place-based group of practices in the West Midlands. National prescribing data were obtained from OpenPrescribing, and ADR data from the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme (01/2020–12/2024). Analyses included demographic trends, treatment efficacy (HbA1c and weight), and socioeconomic comparisons using the Socioeconomic Index for Small Areas (SEISA) deciles. Findings: Semaglutide prescribing in the GP surgeries studied peaked in 2022 and declined thereafter, mirroring national trends. Prescribing of semaglutide mirrored the ethnic make-up of the region studied with a notable exception of White British. Mean HbA1c fell by 10.8 mmol/mol and weight by 4.8%. ADR incidence in the population studied (1.85%) exceeded national reporting rates (0.20%). Prescribing was highest in practices serving the most deprived communities. Conclusions: Semaglutide is effective in reducing HbA1c and weight in real-world settings. However, ADRs remain underreported. Socioeconomic deprivation was strongly associated with higher prescribing rates. Greater attention to equitable access and pharmacovigilance is warranted.Keywords
This publication has 18 references indexed in Scilit:
- Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system databaseEndocrine, 2024
- Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesityNature Medicine, 2024
- Racial, ethnic and regional differences in the effect of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trialsJournal of the Royal Society of Medicine, 2023
- Health inequalities and diabetesPractical Diabetes, 2023
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesNew England Journal of Medicine, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agentsJournal of Clinical Pharmacy and Therapeutics, 2020
- Semaglutide for the Treatment of Type 2 Diabetes MellitusJournal of Pharmacy Technology, 2018
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysisInternational Journal of Epidemiology, 2011